| scholarly article | Q13442814 |
| P50 | author | Oumeya Adjali | Q115599895 |
| Nicolas Jaulin | Q57387022 | ||
| P2093 | author name string | Jack-Yves Deschamps | |
| Ignacio Anegon | |||
| Philippe Moullier | |||
| Gaëlle Tilly | |||
| Yan Cherel | |||
| Aurélie Moreau | |||
| Céline Vandamme | |||
| Mercedes Segovia | |||
| Maria Cristina Cuturi | |||
| Marie Devaux | |||
| Mickaël Guilbaud | |||
| Johanne Le Duff | |||
| P2860 | cites work | Tolerogenic dendritic cells and negative vaccination in transplantation: from rodents to clinical trials | Q21131223 |
| Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway | Q24310325 | ||
| Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers | Q33782809 | ||
| Regulatory dendritic cell infusion prolongs kidney allograft survival in nonhuman primates | Q33804736 | ||
| AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 | ||
| Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. | Q34193317 | ||
| Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. | Q34266296 | ||
| Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial | Q34311144 | ||
| Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now? | Q34338355 | ||
| MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAV | Q36142477 | ||
| Control of erythropoietin delivery by doxycycline in mice after intramuscular injection of adeno-associated vector | Q77145715 | ||
| Migration of human dendritic cells after injection in patients with metastatic malignancies | Q77804763 | ||
| Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance | Q80358513 | ||
| Donor-specific allograft tolerance by administration of recipient-derived immature dendritic cells and suboptimal immunosuppression | Q81681979 | ||
| Tolerogenic dendritic cells actively inhibit T cells through heme oxygenase-1 in rodents and in nonhuman primates | Q83779548 | ||
| Sensitization or tolerance to Mycobacterium leprae antigen by route of injection. | Q36337864 | ||
| Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells | Q36369028 | ||
| Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. | Q36438711 | ||
| Deficiency in MyD88 Signaling Results in Decreased Antibody Responses to an Adeno-Associated Virus Vector in Murine Pompe Disease | Q36574550 | ||
| Tolerogenic dendritic cells and the quest for transplant tolerance | Q36879029 | ||
| Immune responses to AAV vectors: overcoming barriers to successful gene therapy | Q36983740 | ||
| Tolerogenic Donor-Derived Dendritic Cells Risk Sensitization In Vivo owing to Processing and Presentation by Recipient APCs. | Q37077325 | ||
| Protection of islet grafts through transforming growth factor-β-induced tolerogenic dendritic cells. | Q37110557 | ||
| The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice | Q37286686 | ||
| Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy | Q37364038 | ||
| Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression | Q37384103 | ||
| Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD mice | Q37490637 | ||
| Human tolerogenic DC-10: perspectives for clinical applications. | Q38078109 | ||
| Tolerogenic dendritic cells as a therapy for treating lupus | Q38115047 | ||
| Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature. | Q38186768 | ||
| Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle | Q39639059 | ||
| Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in nonhuman primates after intramuscular injection of recombinant adeno-associated virus | Q39685864 | ||
| Superiority of bone marrow-derived dendritic cells over monocyte-derived ones for the expansion of regulatory T cells in the macaque | Q40092510 | ||
| Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. | Q41180997 | ||
| Comparative study of clinical grade human tolerogenic dendritic cells | Q42836981 | ||
| Cell therapy with autologous tolerogenic dendritic cells induces allograft tolerance through interferon-gamma and epstein-barr virus-induced gene 3. | Q43544645 | ||
| Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. | Q43727676 | ||
| Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle | Q44474527 | ||
| Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans | Q45221904 | ||
| A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. | Q45360452 | ||
| Adeno-associated virus capsid structure drives CD4-dependent CD8+ T cell response to vector encoded proteins | Q45384856 | ||
| Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults | Q45409947 | ||
| Correction of feline lipoprotein lipase deficiency with adeno-associated virus serotype 1-mediated gene transfer of the lipoprotein lipase S447X beneficial mutation | Q45416450 | ||
| Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector | Q45855552 | ||
| Erythropoietin gene therapy leads to autoimmune anemia in macaques | Q45871284 | ||
| Autoimmune anemia in macaques following erythropoietin gene therapy | Q45871935 | ||
| Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation | Q45879591 | ||
| Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. | Q45879597 | ||
| Major role of local immune responses in antibody formation to factor IX in AAV gene transfer | Q45883516 | ||
| Infusion of stably immature monocyte-derived dendritic cells plus CTLA4Ig modulates alloimmune reactivity in rhesus macaques. | Q50946765 | ||
| Prolongation of heart allograft survival by immature dendritic cells generated from recipient type bone marrow progenitors. | Q53874628 | ||
| Safety and Efficacy of Regional Intravenous (RI) Versus Intramuscular (IM) Delivery of rAAV1 and rAAV8 to Nonhuman Primate Skeletal Muscle. | Q54457954 | ||
| Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression | Q56975206 | ||
| Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state | Q57779701 | ||
| Interleukin‐10 differentially regulates B7‐1 (CD80) and B7‐2 (CD86) expression on human peripheral blood dendritic cells | Q71815204 | ||
| Mammalian and viral IL-10 enhance C-C chemokine receptor 5 but down-regulate C-C chemokine receptor 7 expression by myeloid dendritic cells: impact on chemotactic responses and in vivo homing ability | Q73966632 | ||
| P921 | main subject | dendritic cell | Q506253 |
| P304 | page(s) | 14028 | |
| P577 | publication date | 2014-07-23 | |
| P1433 | published in | Molecular Therapy. Methods & Clinical Development | Q27725341 |
| P1476 | title | Generation and in vivo evaluation of IL10-treated dendritic cells in a nonhuman primate model of AAV-based gene transfer | |
| P478 | volume | 1 |
| Q91938979 | Five Years of Successful Inducible Transgene Expression Following Locoregional Adeno-Associated Virus Delivery in Nonhuman Primates with No Detectable Immunity |
| Q90529882 | Generation and functional assessment of nonhuman primate regulatory dendritic cells and their therapeutic efficacy in renal transplantation |
| Q40184422 | IL-21/anti-Tim1/CD40 ligand promotes B10 activity in vitro and alleviates bone loss in experimental periodontitis in vivo |
| Q26752803 | Production and clinical development of nanoparticles for gene delivery |
| Q52665595 | Tolerogenic Dendritic Cells in Solid Organ Transplantation: Where Do We Stand? |
| Q39013872 | Tolerogenic dendritic cell therapy in organ transplantation |
Search more.